Table 3.
Characteristics of hepatitis C virus (HCV) cohort
| Number of patients (total) | 1404 |
| Age at the beginning of follow-up: median (range) | 47 (16–87) |
| Gender (%) | |
| Male | 604 (43.0) |
| Female | 281 (20.0) |
| Unknown | 519 (37.0) |
| Ethnicity (%) | |
| White | 359 (25.6) |
| Mixed | 11 (0.8) |
| Asian | 53 (3.8) |
| Black | 41 (2.9) |
| Other | 49 (3.5) |
| Unknown | 891 (63.4) |
| HCV genotype | |
| 1a (%) | 351 (25.0) |
| 1b (%) | 144 (10.3) |
| 1 other (%) | 48 (3.4) |
| 2 (%) | 58 (4.1) |
| 3a (%) | 225 (16.0) |
| 3 other (%) | 50 (3.6) |
| 4 (%) | 69 (4.9) |
| 5 (%) | 2 (0.1) |
| 6 (%) | 3 (0.2) |
| Unknown (%) | 454 (32.3) |
| HBV coinfection | |
| Yes (%) | 75 (5.4) |
| No (%) | 1097 (78.1) |
| Unknown (%) | 232 (16.5) |
| HIV coinfection | |
| Yes (%) | 60 (4.3) |
| No (%) | 1077 (76.7) |
| Unknown (%) | 267 (19.0) |
| Documented comorbidities | |
| Diabetes (%) | 111 (7.9) |
| Depression (%) | 253 (18.0) |
| Chronic kidney disease (%) | 18 (1.3) |
| Coagulation disorder (%) | 47 (3.3) |
| Cryoglobulinaemia (%) | 7 (0.5) |
| Cancer (%) | 77 (5.4) |
| Liver cancer (%) | 16 (1.1) |
| Other cancer (%) | 61 (4.3) |
| Severity of liver disease | |
| Cirrhosis (%) | 408 (29.1) |
| Decompensated (%) | 121 (8.6) |
| Child–Pugh Score: median (IQR) | 6.0 (2.0) |
| Fibroscan stiffness: median (IQR) | 8.4 (11.6) |
| MELD Score: median (IQR) | 9.0 (4.7) |
| Patients treated (%)* | 914 (65.1) |
For a continuous variable, median and the IQR are calculated, for a categorical variable, the number and the percentage of patients is provided.
*Patients who had at least one episode of treatment recorded.
MELD, Model For End-Stage Liver Disease.